Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Ann Dermatol. 2011 Aug;23(3):357-61. doi: 10.5021/ad.2011.23.3.357. Epub 2011 Aug 6.

Treatment of keratoacanthoma with 5% imiquimod cream and review of the previous report.

Author information

  • 1Department of Dermatology, Seoul National University College of Medicine, Seoul, Korea.

Abstract

Keratoacanthoma (KA) is a benign epidermal tumor, characterized by rapid and abundant growth, a tendency toward spontaneous regression and histopathologic similarity to squamous cell carcinoma (SCC). Because KA can be easily misdiagnosed as SCC, surgery is considered the treatment of choice. Recently, regression of KAs following application of 5% imiquimod cream (Aldara®) has been reported. We present 4 cases of KA treated with topical imiquimod, applied 3 to 4 times a week. Obvious improvement was observed after 4 to 6 weeks of application and the lesions were almost cleared leaving scars after 9 to 11 weeks. These results show that topical imiquimod can be an effective option for the conservative management of KA as previously reported. We also suggest that lesions treated with imiquimod cream should be considered for biopsy to judge histopathological remission after 5 to 8 weeks of application to shorten the duration of the treatment.

KEYWORDS:

Imiquimod; Keratoacanthoma

PMID:
21909208
[PubMed]
PMCID:
PMC3162267
Free PMC Article

Images from this publication.See all images (4)Free text

Fig. 1
Fig. 2
Fig. 3
Fig. 4
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Korean Dermatological Association Icon for PubMed Central
    Loading ...
    Write to the Help Desk